文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

同时抑制肿瘤坏死因子受体1与基质金属蛋白酶8可完全防护急性炎症与脓毒症

Simultaneous Inhibition of Tumor Necrosis Factor Receptor 1 and Matrix Metalloproteinase 8 Completely Protects Against Acute Inflammation and Sepsis.
PubMed 文献 · Crit Care Med · 2018-01-01
一句话结论在脓毒症患者中基质金属蛋白酶8与肿瘤坏死因子受体1血浆水平与病情严重度相关,动物实验中同时抑制两者可改善生存。

该研究为观察性人体预试验加前瞻性对照动物实验,纳入13例脓毒症患者连续7天并在入ICU 24小时内采集血浆与全血RNA,检测基质金属蛋白酶8与肿瘤坏死因子受体1水平。结果显示两者血浆水平与SOFA评分(r分别为0.51和0.58)及白介素6水平(r分别为0.59和0.52)呈正相关。在敲除基质金属蛋白酶8和/或肿瘤坏死因子受体1的C57BL/6小鼠中,双基因敲除小鼠在内毒素血症和盲肠结扎穿孔模型中生存优于单基因敲除与野生型小鼠。在盲肠结扎穿孔模型中使用同时阻断两者的双特异性Nanobody共处理,生存率较未处理小鼠改善(28% vs 19%)。作者认为抑制基质金属蛋白酶8和肿瘤坏死因子受体1可能具有治疗脓毒症的潜力。

要点

  • 13例脓毒症患者中,基质金属蛋白酶8与肿瘤坏死因子受体1血浆水平均与SOFA评分正相关(r分别为0.51和0.58)。
  • 同一组13例患者中,基质金属蛋白酶8与肿瘤坏死因子受体1血浆水平均与白介素6水平正相关(r分别为0.59和0.52)。
  • 双基因敲除小鼠在内毒素血症和盲肠结扎穿孔模型中生存优于单基因敲除与野生型小鼠。
  • 盲肠结扎穿孔模型中双特异性Nanobody共处理组生存率28%,未处理组19%。
  • 作者认为同时抑制基质金属蛋白酶8和肿瘤坏死因子受体1可能具有治疗脓毒症的潜力。

适用人群与场景

  • 脓毒症患者13例,入ICU 24小时内及连续7天采集血浆与全血RNA。
  • C57BL/6小鼠,包括基质金属蛋白酶8和/或肿瘤坏死因子受体1缺陷小鼠,接受内毒素血症和盲肠结扎穿孔建模。

研究设计与关键结果

  • 研究类型为观察性人体预试验加前瞻性对照动物实验,人体部分纳入13例脓毒症患者,动物部分使用C57BL/6小鼠。
  • 13例脓毒症患者中,基质金属蛋白酶8血浆水平与SOFA评分正相关(r=0.51),肿瘤坏死因子受体1血浆水平与SOFA评分正相关(r=0.58)。
  • 13例脓毒症患者中,基质金属蛋白酶8血浆水平与白介素6水平正相关(r=0.59),肿瘤坏死因子受体1血浆水平与白介素6水平正相关(r=0.52)。
  • 双基因敲除小鼠在内毒素血症和盲肠结扎穿孔模型中生存优于单基因敲除与野生型小鼠。
  • 盲肠结扎穿孔模型中,双特异性Nanobody共处理组生存率28%,未处理组19%。

证据类型、等级与局限

  • 证据类型为观察性人体预试验加前瞻性对照动物实验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为抑制基质金属蛋白酶8和肿瘤坏死因子受体1可能具有治疗脓毒症的潜力,并提供了双特异性Nanobody在盲肠结扎穿孔模型中有效的原理验证。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Sepsis causes very high mortality and morbidity rates and remains one of the biggest medical challenges. This study investigates whether plasma levels of both matrix metalloproteinase 8 and tumor necrosis factor receptor 1 are associated with sepsis severity and also investigates the therapeutic applicability of simultaneous inhibition of the two molecules in sepsis.

DESIGN: Observational human pilot study-prospective controlled animal study.

SETTING: University hospital and research laboratory.

SUBJECTS: Sepsis patients and C57BL/6 mice deficient for matrix metalloproteinase 8 and/or tumor necrosis factor receptor 1.

INTERVENTION: Plasma and whole blood RNA were collected from 13 sepsis patients for 7 consecutive days and within 24 hours of admission to ICU. Matrix metalloproteinase 8 and tumor necrosis factor receptor 1 plasma and expression levels were determined in these patients. Mice deficient for both matrix metalloproteinase 8 and tumor necrosis factor receptor 1 were generated and subjected to endotoxemia and cecal ligation and puncture. Additionally, a bispecific Nanobody that simultaneously blocks matrix metalloproteinase 8 and tumor necrosis factor receptor 1 was created.

MEASUREMENTS AND MAIN RESULTS: Plasma levels of matrix metalloproteinase 8 and tumor necrosis factor receptor 1 were positively correlated with the Sequential Organ Failure Assessment score (r, 0.51 and 0.58) and interleukin 6 levels (r, 0.59 and 0.52) in 13 sepsis patients. Combined elimination of tumor necrosis factor receptor 1 and matrix metalloproteinase 8 in double knockout mice resulted in superior survival in endotoxemia and CLP compared with single knockouts and wild-type mice. Cotreatment with our bispecific Nanobody in CLP resulted in improved survival rates (28% vs 19%) compared with untreated mice.

CONCLUSIONS: Inhibition of matrix metalloproteinase 8 and tumor necrosis factor receptor 1 might have therapeutic potential to treat sepsis and proof-of-principle was provided as therapeutics that inhibit both tumor necrosis factor receptor 1 and matrix metalloproteinase 8 are effective in CLP.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Steeland S, Van Ryckeghem S, Vandewalle J, et al. Simultaneous Inhibition of Tumor Necrosis Factor Receptor 1 and Matrix Metalloproteinase 8 Completely Protects Against Acute Inflammation and Sepsis. Crit Care Med. 2018. PMID: 29095202. doi:10.1097/CCM.0000000000002813

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。